Top Tech Companies (124)
Don't see your company?
Create a company profile
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.
Entia is an oncology service provider supporting more effective cancer care by predicting and preventing treatment side effects. Our unique remote patient monitoring solutions, including the world's first at-home full blood count analyser, identify patients at risk of complications early on and enable timely interventions that can result in more time on treatment, fewer unplanned hospitalisations and the potential deliver better survival outcomes. We're proud to be partnered with some of the largest global oncology centres and supporting blockbuster therapies from industry leaders. Together, we're unlocking the full potential of cancer therapy.
We started Samphire Neuroscience to build a world where women everywhere have access to scientifically validated wearable technology for their health needs, without having to sacrifice on technology, design or lifestyle. Building on more than thirty years of research and clinical experience, we are developing wearable neurotechnology, the Samphire Headband, that addresses a range of menstrual-cycle related challenges. Want to know more? Reach out to us via [email protected]
Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery. Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing tools to address the challenges of working with machine learning and quantum simulations in drug discovery. This strategy significantly improves the quality of new drugs being produced, as well as reduces discovery time. Our advisors and partners include leading academics and providers in the fields of quantum computing, AI and machine learning and drug discovery. In addition to our in-house discovery programs, we are interested in drug discovery collaborations with pharmaceutical and biotech companies seeking new approaches to novel, first in class, best in class or next generation inhibitors for validated or intractable enzyme targets.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders
Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation
We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
QIO Technologies is a sustainability tech company delivering Industrial IoT AI software products supporting energy-intensive and asset-heavy Industrial, Data Center and Telecom companies to reduce greenhouse gas emissions, improve energy efficiency, and accelerate operational sustainability. QiO developed its Foresight Sustainability Suite™ in response to the difficulties faced by industry in leveraging large, disparate sources of operational data to reduce GHG emissions and improve operational efficiency. By applying its AI optimisation technology in sectors ranging from automotive, steel, glass, cement, oil & gas, data centers and telecoms, Foresight Sustainability Suite™ has delivered up to 20% savings on energy and maintenance costs and reduced GHG emissions by up to 10%. QiO’s newest product, Foresight Optima DC+™, was developed in partnership with Intel to meet the needs of energy-intensive data centers. Foresight Optima DC+™ has delivered energy savings and emissions reductions of up to 50% in data centers worldwide by analysing energy consumption and making real-time adjustments to individual servers. QiO’s Foresight Sustainability Suite™ operates by collecting data from industrial assets ranging from kilns, furnaces, boilers and compressors to cooling systems and data center servers. Using AI, Foresight Sustainability Suite™ identifies and implements real-time actions that optimise energy efficiency and resource use, helping customers make rapid reductions in GHG emissions, energy use, production costs and waste. With businesses under pressure to meet international sustainability reporting standards, Foresight Sustainability Suite™ also automates real-time ESG reporting, enabling every customer to track and report Scope 1 and Scope 2 emissions.
Based in London, Hoxton Farms is creating a deliciously fatty future. We craft cruelty-free, sustainable fats to combine with plant protein for delicious meat alternatives
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom
BlakBear tells you how fresh your food is. We replace shelf-life on fish and meat with a sensor that actually knows. Founded by scientists from Imperial College, we sell freshness sensors and a cloud API, to improve quality control, add shelf-life and cut food waste from producer to consumer.
Biocentis is an Imperial College London spin-out on a mission to develop eco-friendly genetic solutions to effectively and safely control the dangerous insect species that spread disease to humans, reduce biodiversity, or threaten food security. We leverage CRISPR to develop self-limiting gene drive technologies that are biological, environmentally friendly, and can be tailored to obtain levels of control that are suitable for a broad range of applications. Building on a unique proprietary technological platform, invented by our founders at Imperial College London and applicable to all insect species, Biocentis aims to re-imagine the future of biocontrol. We want to empower communities around the world to tackle the most dangerous insect vectors of disease, to preserve biodiversity and to protect agricultural crops from harmful insect pests. Our vision is a more sustainable world, capable of feeding a growing population and free of vector-borne disease. With offices in Milan and London and a presence in the US, we employ a diverse and accomplished team with unparalleled experience in the scientific and technological fields and an outstanding track record in company building and management. We are also growing very fast, and we encourage you to reach out if you want to be part of our journey.
All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 8500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2021 Key Financials: €5.8 billion global revenue Specialties: Neurology, Immunology
Hidden within our planet's vast biodiversity are solutions to some of humanity's greatest challenges, with the potential to deliver sustainable food supplies, revolutionary manufacturing capabilities, and a new generation of medicines. At Basecamp Research, we are building BaseDiscovery, a platform technology that will use next-gen DNA analysis and environmental monitoring to connect the dots and improve our understanding of the natural world. Our team uses a unique and fully portable laboratory capable of rapidly analysing nature anywhere on Earth, discovering novel solutions to the world's most pressing challenges
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
SIME is a clinical AI company applying medical excellence, proprietary AI and data ingenuity to deliver rapid respiratory intensive care diagnostics for acute unmet needs. Our clinically proven technology enables early intervention in life-threatening diseases - improving outcomes and reducing costs.
Pangaea Data is London and South San Francisco based provider of a software product platform to help healthcare and pharmaceutical providers to find untreated patients and bring them into screening. Such untreated patients include undiagnosed, misdiagnosed, miscoded , uncontrolled and at risk patients who comprise up-to 90% of the patient population across hard to diagnose conditions. Pangaea achieves so by mimicking a clinician's manual process to achieve the same based on clinical guidelines so the results are explainable for clinicians and there is zero disruption for clinical and IT teams. The founders at Pangaea have secured more than $300 million in research funding through their work, which includes a $110 million grant to apply Large Language Models (LLMs) in Medicine. All customer success stories and peer-reviewed publications are available through Pangaea's website.
